ArticleAnnals of surgical oncology2026
Use of an Externalized Pancreatic Stent During Robotic Pancreaticoduodenectomy.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPostoperative pancreatic fistula (POPF) is a major contributor to morbidity and mortality after pancreaticoduodenectomy (PD)
methodsThis video demonstrates our technique of using an externalized pancreatic stent during robotic PD. We conducted a retrospective review of patients who underwent robotic PD with externalized pancreatic duct stent placement at a single academic institution. Fistula risk was graded using the Fistula Risk Score (FRS)
resultsOf 67 consecutive patients, 44.8% were female and the median age was 68 years. The most common indication for PD was pancreatic ductal adenocarcinoma (PDAC) (47.8%), followed by cystic neoplasms (22.4%) and neuroendocrine tumors (11.9%); 75% of patients with PDAC received neoadjuvant chemotherapy for borderline resectable disease, and 21.9% underwent preoperative radiation. Most (70.1%) had an intermediate risk of POPF using FRS, and 19.4% were classified as high risk based on the Alternative FRS. The overall POPF rate was 17.9% (biochemical leak
conclusionsWe report the placement of an externalized pancreatic stent during robotic PD, which has not been previously described in robotic surgery. This method is technically feasible and is associated with very low rates of fistula-related complications.
Indexed as
Identifiers
42334718What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.